Table of Contents
“There wasn’t a solution in the past, so I think we are offering something unique. The available solution essentially is phase change material in styrofoam boxes – when you open it, the temperature is gone and CO2 is not controlled. What we have developed is a completely controlled solution that is even GMP compliant.”
“More and more cell types cannot be frozen anymore. If you think about organoids, mixed cultures, artificial tissues – all of those require warm chain logistics.”
Founded in 2017 as a Fraunhofer EMB spin-off and now headquartered in Norderstedt, near Hamburg, Cellbox Solutions has built the cell box – a portable CO2 incubator that ships living cells at 37°C in their usual media environment, with active CO2 supply, so they arrive vital and ready for immediate use. In September 2023 the company filed a Device Master File for its shipper technology with the U.S. FDA, and the Cellbox 2.0 platform is designed to support GMP-compliant cell therapy workflows, including 21 CFR Part 11 software compliance. With Bernd Mühlenweg joining as CBO/CFO in early March 2026, Cellbox is now expanding from in-house lab-to-lab transport into clinical trial logistics – the regulated environment where centralised GMP facilities ship samples to external quality-control sites and warm-chain shipment is the only viable option.
At Meeting on the Med 2026, reporting for Onyx, Federico Citterich sat down with Bernd Mühlenweg to find out more.
A special thanks to our Onyx Live sponsors:
Cellares - delivering cell therapy manufacturing excellence at scale across a global network of IDMO smart factories https://www.cellares.com/
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·
Comments